Please check your internet connection and try again.
# Lorazepam
## Overview
Lorazepam is a short-acting benzodiazepine with anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant properties. It is metabolized by glucuronidation, which is independent of the cytochrome P450 system.
## Primary Indications
* Anxiety disorders
* Insomnia
* Status epilepticus
* Preoperative sedation
* Management of acute agitation
## Adult Dosing
* **Anxiety:** Typically 0.5 mg to 2 mg orally every 6 to 8 hours. Maximum daily dose is generally 10 mg.
* **Insomnia:** 2 mg to 4 mg orally at bedtime.
* **Status Epilepticus:** 4 mg intravenous (IV) or intramuscular (IM) injection. May repeat 4 mg after 10 to 15 minutes if seizures persist. Maximum initial dose 8 mg.
* **Preoperative Sedation:** 2 mg to 4 mg IM given 2 hours before surgery.
* **Acute Agitation:** 0.05 mg/kg IM or IV, not to exceed 4 mg per dose. May repeat every 10 to 15 minutes as needed, not to exceed a total dose of 0.1 mg/kg or 10 mg in a 12-hour period.
## Pediatric Dosing
Dosing in pediatrics is less established and should be approached with caution.
* **Status Epilepticus:** 0.05 mg/kg IV or IM, not to exceed 2 mg per dose. May repeat doses every 5 to 10 minutes up to a maximum total dose of 0.1 mg/kg or 4 mg.
* **Sedation/Anxiolysis:** Individualized based on patient weight, age, and clinical condition. Doses vary widely.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dose reduction is typically recommended due to its glucuronidation pathway, but impaired metabolism may prolong effects.
* **Renal Impairment:** No specific dose adjustment is generally recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to lorazepam or other benzodiazepines.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Sedation, drowsiness, dizziness, weakness, ataxia.
* **Less Common:** Confusion, depression, amnesia, paradoxical excitation, respiratory depression (especially with IV administration or in combination with other CNS depressants).
* **Paradoxical Reactions:** Agitation, excitement, hallucinations.
* **Withdrawal Symptoms:** Can occur with abrupt discontinuation after prolonged use, including anxiety, insomnia, tremors, muscle cramps, nausea, and potentially seizures.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Potentiates sedation and respiratory depression. Concomitant use requires careful monitoring and may necessitate dose reduction of one or both agents.
* **Theophylline/Aminophylline:** May reduce the sedative effects of lorazepam.
* **Valproic acid:** May increase lorazepam plasma concentrations.
## Monitoring
* Level of consciousness, respiratory rate, and oxygen saturation, especially with IV/IM administration and in combination with other CNS depressants.
* Signs of withdrawal if patient is receiving chronic therapy.
* Hepatic and renal function periodically in patients with impaired function or on long-term therapy.
## Clinical Pearls
* Intravenous lorazepam is the drug of choice for status epilepticus.
* IM administration may be preferred if IV access is difficult or unavailable.
* Avoid rapid IV injection to minimize risk of respiratory depression and hypotension.
* Due to its short half-life, lorazepam may be less suitable for patients requiring long-term maintenance therapy compared to longer-acting benzodiazepines, though it is commonly used.
* Paradoxical reactions are more common in children and the elderly.
* Gradual tapering of the dose is essential to avoid withdrawal symptoms upon discontinuation of chronic therapy.
***
**Disclaimer:** This information is intended for clinical pharmacists and should not replace a thorough review of the official prescribing information and clinical judgment. Always verify current prescribing information before making treatment decisions.
